Latest news, reports, and more from the RedChip Nation.
 
Discovering Tomorrow's Blue Chips Today
April 2, 2021     Contact    
Featured This Week
 
Hoth Therapeutics (NASDAQ: HOTH)
 

 

Hoth has two programs in clinical phases of development. The BioLexa Program addresses an unmet need of a non-steroidal anti-inflammatory (NSAID) in both pediatric and adult populations. The atopic dermatitis market is expected to reach $18B by 2027. The HT-001 clinical program is in the derma-oncology field treating cancer patients with skin toxicity side effects of EGFR (epidermal growth factor receptor) therapy. HT001 is a first of its kind therapeutic for the 90% of EGFR patients that develop skin toxicities for the treatment of lung, breast, colon, and pancreatic cancers. Hoth also has a deep and diverse early preclinical development pipeline. With near-term top-line data, a strong cash position, and a robust clinical pipeline with multiple shots on goal, Hoth’s current market cap does not reflect its potential value. Benchmark Securities has put a buy rating on the stock with a $10.00 price target. Learn more at HOTHinfo.com.

 
 >
Latest News
 
Denver Broncos Sign Esports Entertainment Group (NASDAQ: GMBL) as its Esports Tournament Club Provider in Multi-Year Deal
 >
EVmo (OTC: YAYO) Announces Delivery of its first Fleet of Tesla Vehicles Under Its Fleet Partnership with Tesla
 >
Can-Fite BioPharma (NYSE American: CANF) Reports 2020 Financial Results & Provides Clinical Development Update
 
 
Lantern Pharma (NASDAQ: LTRN) to Present New Data Supporting the Advancement of LP-184 at the AACR Virtual Annual Meeting 2021
 
 
Amesite (NASDAQ: AMST) Amesite (Nasdaq: AMST) Establishes New Paradigm in Surging E-Learning Space
 
 
Goedeker’s (NYSE American: GOED) Acquisition of Appliances Connection Stays on Track—Closes $5M Financing, Strengthening Working Capital to Acquire Inventory to Meet Rising Consumer Demand
 
 
Hoth Therapeutics (NASDAQ: HOTH) Announces Positive Preclinical Results for Novel COVID-19 Therapeutic
 
 
American Resources (NASDAQ: AREC) Announced Closing of $100,000,000 Company Sponsored SPAC's Initial Public Offering - American Acquisition Opportunity Inc.
 
 
RYU Apparel (OTCQB: RYPPF) Announces New Growth Strategy Led by COO Rob Blair and Secured Convertible Debenture Financing with Participation by Canaccord Genuity
 
 
Nemaura Medical (NASDAQ: NMRD) Retains Paul Kennedy as Advisor for International Growth Opportunities and Member of the Executive Advisory Board
 
 
Draganfly (OTCQB: DFLYF) Secures One Million Dollar Flight Services Contract
 
 
LMP Automotive (NASDAQ: LMPX) Acquisition Closing of Bachman-Bernard Chevrolet-Buick-GMC-Cadillac Along with its Associated Real Estate
 
 
Bragg Gaming (OTC: BRGGF) Promotes Richard Carter to Role of CEO
 
 
SinglePoint (OTC: SING) Announces Effectiveness of Reverse Stock Split and Spin off of 1606 Corp.
 
 
DSG Global (OTCQB: DSGT) Sales Continue to Climb with Q1 Sales Surpassing $1.168 Million
 
 
 
Upcoming Zoom Webinar
 
 
 
 

Join Zoom Meeting: zoom.us/j/93228937962
One tap mobile
US: +13017158592,,93228937962#,,,,*250766# or
+13126266799,,93228937962#,,,,*250766#
Or Telephone:
Dial(for higher quality, dial a number based on your current location):
+1 646 558 8656 US (New York)
+1 301 715 8592 US (Washington D.C)
+1 312 626 6799 US (Chicago)
+1 669 900 9128 US (San Jose)
+1 253 215 8782 US (Tacoma)
+1 346 248 7799 US (Houston)

Webinar ID: 932 2893 7962
Passcode: 250766
International numbers available:
zoom.us/u/abfNuNm6Jx


 
 
 
 
 
 
 
 
 
 
 
Quote of the Week
 
"If you want to invest in the microcap space buy companies not stocks, if you buy stocks, the daily fluctuations and lack of liquidity will drive you crazy."
- Byron Roth, CEO ROTH Capital
 
 
 
Lesson of the Week
 
Tips on learning when to sell in this week’s lesson.
Read More
 
 
 

 

Latest Videos
 
 
This Week on RedChip TV: Two Biotech’s Entering Phase 3 Trials in 2021
 
This week features two interviews with Hoth Therapeutics (NASDAQ: HOTH) and Can-Fite BioPharma (NYSE AMERICAN: CANF), two exciting biotechs preparing to launch Phase 3 trials in 2021.
 
Watch Now
 
 
 
 
BTCS: Pioneer in Blockchain Space
 
BTCS Inc. (OTCQB: BTCS) is an early entrant in the digital asset market and one of the first U.S. publicly traded companies focused on digital assets and blockchain technologies. BTCS resumed its transaction verification services business segment in the first quarter of 2021 with a focus on validating transactions and operating nodes on proof-of-stake blockchains.
 
Watch Now
 
 
 
 
DeFi Technologies: Transforming the Global Financial System
 
Led by co-founders Wouter Witvoet and Olivier Roussy Newton, who collectively raised $1.4B in their prior two deals, DeFi Technologies (OTC: RDNAF) is well positioned to become a key player in the rapidly growing decentralized finance industry. The market size for the industry is measured in the trillions and spans multiple sectors, including insurance, derivatives, credit and lending, asset management, and exchanges.
 
Watch Now
 
 
 
 
Learn Why Robert Blair, The Visionary Architect Behind Lulu Lemon (LULU) Joined RYU Apparel
 
RYU Apparel (OTCQB: RYPPF), or Respect Your Universe, is an award winning urban athletic apparel brand that engages in the development, marketing, and distribution of apparel, bags and accessories. Our products are engineered for the fitness, training and performance of the multi-discipline athlete. Our products are designed, developed and tested at our corporate headquarters in Vancouver, BC, Canada. Production takes place in factories located in North America and Asia.
 
Watch Now
 
 
 
 
Lantern Pharma: Transforming Cancer Drug Development with A.I.
 
Lantern Pharma (Nasdaq: LTNR) is a clinical stage biotechnology company leveraging its RADR® artificial intelligence (“A.I.”) platform to transform the pace, risk and cost of oncology drug development. RADR® A.I. quickly and efficiently develops precise genetic signatures of disease that underpin the identification of patients for whom its portfolio of oncology drug candidates is likely to have the greatest therapeutic effect. Lantern is currently developing three drug candidates in solid tumors.
 
Watch Now
 
 
 
 
Kiromic BioPharma: AI-Driven Immuno-Oncology Therapy Development
 
Kiromic BioPharma (Nasdaq: KRBP) is revolutionizing next-generation allogenic CAR therapies for solid tumors. The Company’s proprietary target discovery engine, Diamond uses AI and a proprietary neural network to identify development targets, dramatically compressing man years and billions of drug development dollars required to develop new live drugs.
 
Watch Now
 
 
 
 
Aridis Pharmaceuticals: Developing Novel Anti-Infective Therapies
 
Aridis Pharmaceuticals (Nasdaq: ARDS) discovers and develops anti-infectives to be used as add-on treatments to standard-of-care antibiotics. The Company is utilizing its proprietary ʎPEXTM and MabIgX® technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome an infection, and to rapidly manufacture monoclonal antibody (mAbs) for therapeutic treatment of critical infections.
 
Watch Now
 
 
`
 
 
COMSovereign Corporate Overview with CEO & CTO
 
COMSovereign Holding (Nasdaq: COMS) Chairman & CEO Dan Hodges, along with Chief Technology Officer Dr. Dustin McIntire, share insight into the Company’s portfolio of communications technology companies and how they are expected to drive rapid growth in 2021 and beyond. Through strategic acquisitions and organic research and development efforts, COMSovereign has become a U.S.-based communications provider able to provide 4G LTE Advanced and 5G-NR telecom solutions to network operators and enterprises.
 
Watch Now
 
 
 
 
Hoth Therapeutics: Developing a New Generation of Therapies for Unmet Medical Needs
 
Hoth Therapeutics (Nasdaq: HOTH) is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's clinical pipeline is concentrated on drug candidates that improve the quality of life for patients suffering from indications including atopic dermatitis, skin toxicities associated with cancer therapy, chronic wounds, psoriasis, asthma, acne, mast-cell derived cancers & anaphylaxis and pneumonia.
 
Watch Now
 
 
 
 
Can-Fite BioPharma: Advanced Clinical Stage Drug Development
 
Can-Fite BioPharma (NYSE American: CANF) has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancer diseases. The company’s platform technology utilizes the Gi protein associated A3 adenosine receptor (A3AR) as a therapeutic target. A3AR is highly expressed in inflammatory and cancer cells where low expression is found in normal cells, suggesting that the receptor could be a unique target for pharmacological intervention.
 
Watch Now
 
 
 
 
Esports Entertainment Group CEO Discusses Plans for Rapid Growth
 
Interview with CEO of Esports Entertainment Group Inc. (NASDAQ: GMBL), a full stack esports and online gambling company fueled by the growth of video-gaming and the ascendance of esports with new generations. Its mission is to help connect the world at large with the future of sports entertainment in unique and enriching ways that bring fans and gamers together. Esports Entertainment Group and its affiliates are well-poised to help fans and players to stay connected and involved with their favorite esports.
 
Watch Now
 
 
 
 
Alset EHome International: Diversified Operations Accelerating Sustainable Healthy Living
 
Alset EHome International (Nasdaq: AEI) is a diversified holding company principally engaged through its subsidiaries in property development, digital transformation technology and biohealth activities with operations in the United States, Singapore, Hong Kong, Australia and South Korea.
 
Watch Now
 
 
 
 
CBD of Denver: Corporate Overview
 
CBD of Denver (OTC: CBDD) is a full-line CBD and hemp oil company, producing and distributing cannabis and CBD products in Switzerland, Europe, and the US. CBDD is focused on using equity to acquire profitable Swiss assets at attractive valuations to create value for its shareholders and is driven by a passion to improve lives and strengthen communities by unleashing the full potential of cannabis.
 
Watch Now
 
 
 
 
Nano Dimension: CEO Discusses Acquisition Strategy
 
Nano Dimension (NASDAQ: NNDM) is a provider of intelligent machines for the fabrication of Additively Manufactured Electronics (AME). High fidelity active electronic and electromechanical subassemblies are integral enablers of autonomous intelligent drones, cars, satellites, smartphones, and in vivo medical devices.
 
Watch Now
 
 
 
 
American Resources: Next-Generation Raw Materials Supplier for New Infrastructure
 
American Resources Corp. (Nasdaq: AREC) is a next-generation, environmentally and socially responsible supplier of high-quality raw materials to the new infrastructure market. The Company is focused on the extraction and processing of metallurgical carbon, an essential ingredient used in steelmaking, critical rare earth minerals for the electrification market, and reprocessed metal to be recycled.
 
Watch Now
 
 
 
 
Draganfly: Drone Technology Solving Real World Challenges
 
Draganfly (OTCQB: DFLYF) has been a leader in the professional drone industry for more than 20 years, supporting clients with enterprise drone solutions, contract engineering services, custom software, professional unmanned aerial vehicle (UAV) services, and more. From public safety to pop culture, Draganfly has shaped not just the UAV industry, but the way people around the world work and live.
 
Watch Now
 
 
 
 
Genetic Technologies: Innovative Tests to Determine Disease Risk
 
Genetic Technologies (Nasdaq: GENE) is a diversified molecular diagnostics company developing tools for the prediction and assessment of cancer risk to help physicians proactively manage patient health. The Company’s lead products, ‘GeneType for Breast Cancer’ and ‘GeneType for Colorectal Cancer’, are clinically validated risk assessment tests that are first in their class. The Company’s development pipeline includes new tests for COVID-19, Type 2 diabetes, cardiovascular disease, prostate cancer, and melanoma.
 
Watch Now
 
 
 
 
CBD of Denver: High-Growth Business Targeting US and Europe
 
CBD of Denver (OTC: CBDD) is a full-line CBD and hemp oil company, producing and distributing cannabis and CBD products in Switzerland, Europe, and the US. CBDD is focused on using equity to acquire profitable Swiss assets at attractive valuations to create value for its shareholders and is driven by a passion to improve lives and strengthen communities by unleashing the full potential of cannabis.
 
Watch Now
 
 
 
 
Amesite: Award-Winning AI-Driven Learning for Institution
 
Amesite (Nasdaq: AMST) is a high-tech artificial intelligence (AI) software company offering a cloud-based platform and content creation services for K-12, college, university and business education and upskilling. Amesite-offered courses and programs are branded to its customers.
 
Watch Now
 
 
 
 
BioVie: Developing Potential Game-Changing Treatments for Liver Disease
 
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for liver disease. The Company’s drug candidate, BIV201 (continuous infusion terlipressin), has an Orphan Drug designation for the treatment of refractory ascites, FDA Fast Track status, and US patent pending. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS).
 
Watch Now
 
 
 
 
DSG Global: Positioned for Rapid Growth in Electric Vehicle Market
 
DSG Global (OTCQB: DSGT) is an emerging global technology company with an array of interconnecting businesses in some of the fastest growing market sectors.
 
Watch Now
 
 
 
 
Small-Cap NASDAQ Solar Company Positioned for Rapid Growth
 
Delivering competitive, clean energy solutions to customers for more than 15 years, SPI Energy (NASDAQ: SPI) is an established renewable energy player with global operations in key markets in Asia, Australia, North America, and Europe.
 
Watch Now
 
 
 
 
CEO Interview with OLB Group: High-Growth Fintech Company on the Move
 
The OLB Group (NASDAQ: OLB) is led by a team of seasoned industry executives with extensive experience in payments, ecommerce, and mobile commerce. Trading at 3x sales, upside could be significant in an industry where peer comps trade as high as 39x sales. Aegis Capital gave OLB a buy rating and $9 price target in its latest report on the Company. Learn more at OLBGinfo.com.
 
Watch Now
 
 
 
 
Tiziana Life Sciences: CEO Discusses Positive Data from COVID-19 Trial
 
Tiziana Life Sciences (Nasdaq: TLSA) is a clinical stage biotechnology company focused on the discovery and development of novel molecules to treat human disease in oncology and immunology. Tiziana’s two lead drug candidates, Foralumab and Milciclib, uniquely target the root cause of diseases with large unmet needs in multibillion-dollar markets.
 
Watch Now
 
 
 
 
Greenwich LifeSciences: Phase 3 Targeting Recurrent Breast Cancer
 
Greenwich LifeSciences (NASDAQ: GLSI) is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery.
 
Watch Now
 
 
 
 
Bragg Gaming: Technology Infrastructure for the Global Gaming Industry
 
Bragg Gaming Group Inc. (OTC: BRGGF) is a next generation gaming group with cutting-edge technology, leading brands and world-class management expertise, developing into a global gaming force. Formed by a team of gaming industry experts, Bragg's main portfolio is ORYX Gaming, an innovative B2B gaming technology platform and casino content aggregator.
 
Watch Now
 
 
 
 
Order Small Stocks, Big Money Today!
 
Dave Gentry is the author of Small Stocks, Big Money: Interviews With Microcap Superstars. Published by Wiley, this first-hand perspective on the fast world of microcap investing is now available for purchase.
 
 
MidSouth Week in Review
 
The number of people seeking unemployment benefits fell sharply last week to 684,000, dropping to its lowest level since the pandemic began.
Read More
 
 
 
 
About RedChip
 
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
 
RedChip Disclosure
 
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures.
 
 
     
 
 
Copyright © 2020 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.